No headlines found.
No press releases found.
No news found.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
Regentis Biomaterials Ltd. trades on the AMEX stock market under the symbol RGNT.
As of December 4, 2025, RGNT stock price climbed to $7.50 with 330,714 million shares trading.
RGNT has a market cap of $36.97 million. This is considered a Sub-Micro Cap stock.
